AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 17, 2019 at 11:12 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Shares of AbbVie Inc. ABBV, +0.08% fell 1.8% in premarket trade after the company announced that interim data from a Phase 3 trial of glioblastoma drug Depatux-M did not show any survival benefit to patients.

    article source